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Abstract
Background
Loiasis is a parasitic infection endemic in the African rain forest caused by the filarial nema-
tode Loa loa. Loiasis can be co-endemic with onchocerciasis and/or lymphatic filariasis.
Ivermectin, the drug used in the control of these diseases, can induce serious adverse reac-
tions in patients with high L loamicrofilaraemia (LLM). A drug is needed which can lower
LLM below the level that represents a risk so that ivermectin mass treatment to support
onchocerciasis and lymphatic filariasis elimination can be implemented safely.
Methodology
Sixty men and women from a loiasis endemic area in Cameroon were randomized after
stratification by screening LLM (30000, 30001–50000, >50000) to three treatment arms:
two doses albendazole followed by 4 doses matching placebo (n = 20), six doses albenda-
zole (n = 20) albendazole or 6 doses matching placebo (n = 20) administered every two
months. LLM was measured before each treatment and 14, 18, 21 and 24 months after the
first treatment. Monitoring for adverse events occurred three and seven days as well as 2
months after each treatment.
Principal Findings
None of the adverse events recorded were considered treatment related. The percentages
of participants with 50% decrease in LLM from pre-treatment for 4 months were 53%,
17% and 11% in the 6-dose, 2-dose and placebo treatment arms, respectively. The differ-
ence between the 6-dose and the placebo arm was significant (p = 0.01). The percentages
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of participants with LLM < 8100 mf/ml for4 months were 21%, 11% and 0% in the 6-dose,
2-dose and placebo treatment arms, respectively.
Conclusions/ Significance
The 6-dose regimen reduced LLM significantly, but the reduction was insufficient to elimi-
nate the risk of severe and/or serious adverse reactions during ivermectin mass drug
administration in loiasis co-endemic areas.
Author Summary
Loiasis is a big obstacle for the elimination of onchocerciasis and lymphatic filariasis in
Central Africa in areas where loiasis is endemic. In these areas, some subjects who are
heavily infected (microfilaraemia> 30 000 microfilariae/ml blood) can develop severe and
serious adverse reactions to ivermectin. In rare cases, these have been fatal. A way of pre-
venting these reactions could be to administer a treatment that decreases the microfilarea-
mia in all subjects below the risk level before mass treatment with ivermectin. Building on
results of previous studies, this randomised placebo-controlled trial evaluated the efficacy
and safety of two or six doses of albendazole administered every two months on the micro-
filaraemia of Loa loa. Six doses led to a decrease in microfilaraemia by at least 50% for at
least four months in 53% of participants. However, it did not reduce the microfilaraemia
below the risk level in all participants. Therefore, this regimen has not sufficient efficacy to
prevent severe adverse reactions to ivermectin.
Introduction
Loiasis is a parasitic infection endemic in the African equatorial rain forest areas, caused by the
filarial nematode Loa loa. It is estimated that at least 14.4 million people live in loiasis endemic
areas [1]. Clinical manifestations include chronic intense itching and transient localized edema
[2]. The chronic eosinophilia observed in infected individuals has been associated with endo-
myocardial fibrosis and related heart failure [3, 4]. Spontaneous encephalitis has been
described in some heavily infected patients [5]. As for other neglected tropical diseases, the lim-
ited geographic distribution of loiasis and the fact that it mainly affects poor rural populations
have limited research on this disease [6].
There is currently no safe and effective treatment. Diethylcarbamazine is effective against
the larvae and adult Loa loa [7], but can cause serious adverse reactions (SAR, for definition
see Table 1 [8]), such as meningoencephalitis, which can be fatal [9, 10]. The rapid and massive
effect of ivermectin on Loa loa blood-dwelling microfilariae can also lead to severe adverse
drug reactions (ADRs, Table 1 [8]), including SARs such as a cerebral malaria-like encephalop-
athy which requires hospitalization, can lead to coma and is often fatal [11, 12]. The mecha-
nisms of these adverse reactions are not well understood. Three mechanisms have been
postulated, including (1) the obstruction of the cerebral microcirculation in consequence of
massive amounts of paralyzed or dead microfilariae, (2) the penetration of live microfilariae
into the brain tissue following treatment, and (3) the inflammatory processes in the brain
resulting from massive release of antigen from dead microfilariae [13].
The current evidence suggests that the risk of ADRs post-ivermectin is positively correlated
with Loa loamicrofilaraemia (LLM). The relatively low number of participants with known
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pre-treatment LLM and adverse event data available from prospective studies [14, 15] together
with the likely underreporting of SARs and non-serious ADRs and the lack of pre-treatment
LLM values from mass treatment with ivermectin [16], do not permit a definition of the mini-
mum pre- treatment LLM that puts subjects at risk for development of severe ADRs and/or
SARs. The study by Gardon and colleagues showed that a pre-treatment LLM8100mf/ml is
associated with significantly increased risk of 'marked reactions' (defined by the investigators
as reactions accompanied by functional impairment requiring assistance for several days) as
well as 'serious reactions' (SR, including (a) non-neurological reactions associated with func-
tional impairment which required at least a week of full-time assistance to resume normal
activities and (b) reactions with objective neurological signs with hospital admission). It was
estimated that participants with pre-treatment LLM50000 mf/ml were 1000 times more
likely to develop SR and that those with LLM>30000 were more than 200 times more likely to
develop SR than non-infected participants [15].
Table 1. Adverse event terminology and definitions.
Term (Abbreviation) Deﬁnition [8]
Adverse event (AE) Any untoward medical occurrence in a patient or clinical
investigation subject administered a pharmaceutical product
and which does not necessarily have to have a causal
relationship with this treatment.
Adverse drug reaction (ADR) For marketed medicinal products: A response to a drug which is
noxious and unintended and which occurs at doses normally
used in man for prophylaxis, diagnosis, or therapy of disease or
for modiﬁcation of physiological function.
For new medicinal products or new uses of approved products:
all noxious and unintended responses to a medicinal product
related to any dose should be considered adverse drug
reactions.
Serious Adverse Event (SAE), Serious
Adverse Reaction (SAR)
A serious adverse event (experience) or reaction is any
untoward medical occurrence that at any dose:
- results in death,
- is life-threatening,
NOTE: The term "life-threatening" in the deﬁnition of "serious"
refers to an event in which the patient was at risk of death at
the time of the event; it does not refer to an event which
hypothetically might have caused death if it were more severe.
- requires inpatient hospitalisation or prolongation of existing
hospitalisation,
- results in persistent or signiﬁcant disability/incapacity, or
- is a congenital anomaly/birth defect.
Important medical events that may not be immediately life-
threatening or result in death or hospitalisation but may
jeopardise the patient or may require intervention to prevent
one of the other outcomes listed in the deﬁnition above should
also usually be considered serious.
Note: The terms 'serious' and 'severe' are not synonymous. The
term "severe" is often used to describe the intensity (severity) of
a speciﬁc event (as in mild, moderate, or severe myocardial
infarction); the event itself, however, may be of relatively minor
medical signiﬁcance (such as severe headache). This is not the
same as "serious," which is based on patient/event outcome or
action criteria usually associated with events that pose a threat
to a patient's life or functioning. Seriousness (not severity)
serves as a guide for deﬁning regulatory reporting obligations.
doi:10.1371/journal.pntd.0004492.t001
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Onchocerciasis and lymphatic filariasis (LF) are two of the 17 neglected tropical diseases
according to the WHO classification (http://www.who.int/neglected_diseases/diseases/en/).
The number of people at risk of O. volvulus infection was estimated to be 113.5 million, and
those at risk of LF to be 1.34 billion worldwide [17]. The cornerstone of the fight against oncho-
cerciasis and LF in highly endemic areas in Africa is mass community treatment with ivermec-
tin (Mectizan) alone and in combination with albendazole, respectively.
In loiasis endemic areas where onchocerciasis is mesoendemic or hyperendemic (i.e. preva-
lence of onchocercal skin nodules in adult males aged20 years higher than 20% and 40%
respectively), ivermectin mass treatment is justifiable because the benefit of preventing oncho-
cerciasis associated morbidity outweighs the risk of loiasis-related post-treatment adverse reac-
tions [18].
In LF and loiasis co-endemic areas, the control of LF has not yet or only recently started,
partly because of the risk of loiasis-related post-treatment SAEs [19]. This puts the planned
elimination of LF at risk [17]. WHO has recently suggested a provisional strategy for interrup-
tion of LF transmission in loiasis-endemic areas based on biannual treatment with albendazole
complemented with vector control [20, 21].
Studies in Senegal and Mali have shown that 15–17 years of annual or biannual community
directed treatment with ivermectin (CDTI) can result in elimination of O. volvulus transmis-
sion [22, 23]. Furthermore, the prevalence of O. volvulus infection following long term CDTI
has been reduced significantly in many other areas [24, 25]. Consequently, the objectives of the
African Programme for Onchocerciasis Control were expanded from elimination of onchocer-
ciasis as a public health problem to elimination of O. volvulus transmission where feasible [26].
This may require treatment of onchocerciasis in hypoendemic areas co-endemic with loiasis. A
treatment that can safely reduce LLM below the risk threshold for severe ADRs and SARs for a
time sufficiently long to implement ivermectin mass treatment, would be a major contribution
to efforts to control and eliminate onchocerciasis and LF. Such a treatment may also be benefi-
cial for patients suffering from loiasis.
Previous trials of the effect of short-term albendazole treatments (1 to 21 days) have shown
that albendazole results in a slow reduction of LLM, presumably not due to a microfilaricidal
effect but to an effect on the reproductive capacity and/or viability of the macrofilariae. In
these studies, the reduction in LLM was either not as extensive as required and/or the study did
not include significant number of participants with LLM> 30000 mf/ml [27–30]. The LLM
time course in these studies and comparison of the effect of different doses evaluated led to the
hypothesis that multiple exposure of the Loa loamacrofilariae to albendazole at two months
intervals may result in a significant and sustained reduction in LLM.
We report findings from a double-blind, randomized, placebo-controlled trial designed to
evaluate whether 2 and/or 6 doses of 800mg albendazole administered at two-months intervals
can reduce Loa loamicrofilaraemia in patients with pre-treatment LLM>15000 mf/ml by at
least 50% or even to<8100mf/ml for at least 4 months.
Methods
Trial registration
http://www.controlled-trials.com/ISRCTN25831558.
Study design and intervention
This was a double-blind, randomized, placebo-controlled trial with three parallel treatment
arms. Every two months (i.e. at M0, M2, M4, M6, M8, M10), participants received one oral
treatment: (1) 800 mg albendazole (6x albendazole arm), (2) 800 mg albendazole at M0 and
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M2 and matching placebo at M4, M6, M8 and M10 (2x albendazole arm) or (3) matching pla-
cebo (placebo arm). LLM was measured during screening, before each treatment, and 14, 18,
21 and 24 months after the first treatment. Before each treatment, all participants had a general
medical examination, and women up to 55 years underwent a pregnancy test. Three and seven
days after each treatment, participants underwent clinical examination and questioning for any
adverse events, to be followed, if clinically indicated, by a laboratory examination. Prior to the
2nd to 6th treatment and at the 14-months follow up, participants were asked about any adverse
events since the last evaluation.
Study area and population
The study was conducted in the Mvila Division in the rain forest of the Southern Region of
Cameroon in areas with high loiasis endemicity [1], but<20% prevalence of onchocerciasis
(http://www.who.int/apoc/countries/cmr/en/index.html) and thus without CDTI.
Volunteers aged 18–65 years were eligible if they had a LLM>15,000 mf/ml at screening, had
no plans to move out of the area over the following 2 years and had given informed consent. Indi-
viduals with past or current history of neurological or neuropsychiatric disorders, clinical or labo-
ratory evidence of significant liver and kidney disease, anaemia, intestinal helminth infection,
pregnancy, a serious medical condition or any other conditions which should exclude them from
the study in the principal investigator’s (JK) opinion, treatment with benzimidazoles during the
previous 12 months or with self-reported allergy to benzimidazoles were not eligible.
Participants were identified in a two-step procedure: (1) Screening for Loa loa infection:
After community mobilization, screening for Loa loa infection was performed in the study area
from January to March 2007 among all who had given individual written informed consent;
(2) Participant selection: Individuals with LLM>15,000 mf/ml at screening and potentially
willing to participate in the study, received detailed information about the study, gave informed
written consent to study participation and underwent the evaluations to assess their study eligi-
bility. Baseline LLMmeasurement and first treatment took place between 4 and 12 weeks after
screening for loiasis.
Randomization, blinding and treatment compliance
Eligible individuals were stratified by the LLM obtained during screening:30,000 mf/ml,
30,001 to 50,000 mf/ml and>50,000 mf/ml. Within each stratum, participants were assigned
to one of the three treatment arms based on three randomization lists, one for each stratum,
prepared by an independent statistician using a random digit table. Lists of eligible participants
by stratum were provided to an independent pharmacist not otherwise involved in the study
who assigned the treatment on the randomization list for that stratum which corresponded to
the position of the participant on the eligible participant list. The pharmacist then prepared
treatment packages with the required number of 200 mg albendazole and matching placebo
tablets provided by GlaxoSmithKline (GSK).
The treatment packages were provided to the principal investigator (JK) labelled only with
participant identifying information which allowed all but the pharmacist to be blinded.
Treatments were taken orally under direct observation by the investigators, 15–30 minutes
after a fatty meal (fatty buns with additional ~15g butter). The first treatment occurred in
March 2007.
Laboratory procedures
Calibrated blood smears (CBS) to measure LLM were obtained between 11:00 and 15:00 to
account for the diurnal periodicity of L. loamicrofilaria in peripheral blood [31]. For each
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participant, blood collection was done at the same time of day ± 1 hour throughout the study.
Following a finger-prick, 50μl of blood was collected using a 50μl non-heparinized capillary
tube and spread on one labelled slide during screening and across two labelled slides during the
study for ease and accuracy of counting. The slides were dried at room-temperature, then
stained with Giemsa. All Loa loa andMansonella perstansmicrofilariae were counted at 100X
magnification. All slides were read by the same blinded biologist throughout the study. A sec-
ond blinded reading of all slides by that biologist was performed at the end of the study, and
the average of the two readings used for data analysis. Differences between the two readings
did not exceed 5%.
A Reflotron Plus (Roche) was used to measure blood levels of hemoglobin, alanine amino-
transferase (ALAT), aspartate aminotransferase (ASAT), and creatinine. Creatinine clearance
was estimated using the Cockroft-Gault formula. Full blood counts were performed using the
ABX Pentra-120 flow-cytometer. Pregnancy tests were done using AMS ßHCG urine tests.
Unblinding and protocol amendment
The protocol initially planned follow-up to 18 months (M18) after the first treatment. Follow-
ing review of the data after unblinding at M18 by external advisors, a protocol amendment was
put in place for LLMmeasurements 21 and 24 months after the first dose. Participants gave
written informed consent for the extended follow-up. All procedures for CBS blood collection
and reading of slides remained identical.
Outcome measures
The primary efficacy variable was the proportion of participants whose LLM was sustain-
ably reduced by 50% from the pre-treatment value (value obtained before the first treat-
ment) from any time point after the first dose onward. A sustainable reduction was
defined as a reduction at each planned measurement time point over a period of at least
4 months.
Secondary efficacy variables were (1) the proportion of participants whose LLM was sus-
tainably reduced to<8100 mf/ml by strata and by sex, (2) the percent reduction in LLM from
pre-treatment at each time point, (3) time course of LLM.
Safety variables were the frequency of adverse events up to four months after the 6th treat-
ment by type, severity, seriousness and relationship to study drug assessed by the investigator
while blinded. Severity was graded as mild (event is easily tolerated by the participant, causing
minimal discomfort and not interfering with everyday activities), moderate (event is suffi-
ciently discomforting to interfere with everyday activities), severe (event prevents normal
everyday activities) or not applicable (events where intensity is meaningless or impossible to
determine e.g. blindness). Seriousness was determined based on the serious adverse event defi-
nition in the ICH guidelines (any untoward medical occurrence that at any dose results in
death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospi-
talization, results in persistent or significant disability/incapacity or is a congenital anomaly/
birth defect and is related to any dose of a medicinal product or the doses normally used in
man) [8]. Likelihood of relationship of the adverse event to study drug, i.e. presence of adverse
drug reactions (defined as per ICH criteria [8] as 'any noxious and unintended responses to a
medicinal product related to any dose or the doses normally used in man'), was assessed based
on temporal association with drug administration and biological plausibility taking into
account known adverse reactions to albendazole, the participant’s underlying clinical state and
known adverse reactions to concomitant treatments.
Effect of Albendazole Every Two Months on Loa loa
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004492 March 11, 2016 6 / 19
Sample size
Assuming that less than 1/1,000,000 placebo treated participants would have a 50% reduction in
LLM for at least 4 months and at least 50% of participants receiving 6 albendazole doses would
have such a reduction, a sample size of 16 participants per treatment provides90% power to
detect the treatment difference at a 2.5% two-sided significance level. The same assumptions
were made regarding the effect of 2 albendazole doses. The significance level of 2.5% was chosen
based on Bonferoni correction for the two planned comparisons. Assuming attrition of 20% of
participants, 20 participants were recruited into each treatment group. 20 participants provide a
probability of 0.87 to detect at least one adverse event with a true frequency of 10%.
Analysis populations
All participants who received at least one dose of study drug were included in the safety analy-
sis and analyzed as randomized.
For the efficacy analyses, participants were analysed as randomized and as part of the stra-
tum they qualified for based on pre-treatment LLM, not the stratum they qualified for based
on the screening LLM used for randomization (see Table 2).
Table 2. Screening and pre-treatment (baseline) characteristics.
Placebo (n = 20) 2 albendazole doses
(n = 20)
6 albendazole doses
(n = 20)
p-
value
Sex
Male 9 10 15 0.14
Female 11 10 5
Age groups
18–39 years old 10 5 5 0.19
40–65 years old 10 15 15
LLM) (mf/ml) of subjects at screening (used for determining eligibility and for randomization) and resulting distribution across strata
N (%) participants with LLM in stratum 15,000–
30,000
11 (55.0) 11 (55.0) 12 (60.0)
N (%) participants with LLM in stratum 30,001–
50,000
5 (25.0) 5 (25.0) 5 (25.0) 0.99*
N (%) participants with LLM in stratum  50,001 4 (20.0) 4 (20.0) 3 (15.0)
LLM geometric mean (95% CI) 32,760 (24,374–44,031) 27,916 (22,014–35,402) 29,510 (22,048–39,497)
LLM arithmetic mean (range) 41,006 (15,900–
155,720)
31,549 (15,000–61,400) 37,061 (15,000–152,840) 0.73t
LLM median (Interquartile range) 27,130 (20,465–47,155) 28,040 (16,485–44,680) 28,550 (17,030–35,285)
LLM) (mf/ml) of subjects before 1st treatment (baseline) and resulting distribution across strata used for data analysis
N (%) participants with LLM in stratum 11,000–
30,000
5 (25.0) 10 (50.0) 11 (55.0)
N (%) participants with LLM in stratum 30,001–
50,000
10 (50.0) 4 (20.0) 5 (25.0) 0.20*
N (%) participants with LLM in stratum  50,001 5 (25.0) 6 (30.0) 4 (20.0)
LLM geometric mean (95% CI) 44059 (32,733–59,302) 35,206 (25,840–47,967) 33,317 (23,811–46,618)
LLM arithmetic mean (range) 55,452 (20,860–
197,060)
44,905 (15,460–185,920) 44,442 (11,040–169,840) 0.29t
LLM median (Interquartile range) 35,690 (29,960–57,055) 30,120 (21,085–64,345) 28,460 (22,975–46,799)
Liver enzymes (UI/ml)
ASAT/SGOT (geometric mean, 95%CI) 28.0 (22.9–34.3) 35.3 (28.5–43.7) 27.0 (23.7–30.8) 0.12
ALAT/SALAT (geometric mean, 95%CI) 16.0 (12.7–20.3) 19.1 (14.9–24.5) 16.9 (13.1–21.8) 0.43
* Fisher’s exact test.
t Kruskall-Wallis test
doi:10.1371/journal.pntd.0004492.t002
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All participants with sufficient post-treatment LLMmeasurements to determine whether or
not they had an LLM reduction for 4 months (i.e. at least two successive measurements over
a minimum of 4 months) were included in the efficacy analyses. An intent-to-treat approach
was taken with participants being evaluated based on the treatment group they were random-
ized to, independent of whether they had received the intended number of doses.
Statistical analysis
Screening and baseline characteristics. Screening and baseline characteristics were com-
pared between treatment arms for imbalance. Proportions were compared using Fisher’s exact
test, and quantitative variables (ASAT, ALAT, LLM) using the non-parametric Kruskal-Wallis
test. Age was transformed into a two-level categorical variable (<40,40 years).
Safety analysis. The number and percentage of participants with adverse events was tabu-
lated by type and severity of adverse event, relationship to study drug and treatment group.
Efficacy data analysis. The proportions of participants with a sustained, i.e.4 months
long reduction in LLM by 50% (primary efficacy variable) were compared between treatment
groups with Fisher's exact test due to the small sample size. The proportion of participants with
sustained reduction of LLM to<8100 mf/ml and the percent reduction in LLM from the pre-
treatment value by follow-up time point was characterized by descriptive statistics. The longi-
tudinal trend in LLM in each treatment arm up to 11–12 months after the last active dose (i.e.
after M2 for the 2x albendazole arm and after M10 for the 6x albendazole arm) and up to the
M21 measurement in the placebo group was estimated by fitting a random-effect multiple lin-
ear model to the log-transformed LLM as the dependent variable, treatment group and follow-
up time as regressors, controlling for age, sex and liver function (ALAT level, in view of the fact
that albendazole is converted to the active metabolite albendazole sulfoxide in the liver) [32],
and an interaction between follow-up time and treatment. For each treatment group, the
resulting regression coefficient was back-transformed to the normal scale by exponentiation
and represents the ratio of geometric mean LLM between consecutive data points. The ran-
dom-effect model takes into account the repeated measurements of LLM over time.
Statistical analyses were performed using Stata 13 (StataCorp LP, College Station, Texas,
USA) or using GraphPad Prism version 6.00 and 6.04 for Windows (GraphPad Software, La
Jolla, California, USA).
Ethics statement
The study protocol and protocol amendment received clearance from Cameroon’s National
Ethics Committee and from the World Health Organization Ethical Review Committee. The
study was granted administrative authorization by the Ministry of Public Health of Cameroon.
Study participants gave written informed consent before any study procedures were
conducted.
Results
A total of 2005 people from 37 communities were included in the screening for Loa loa infec-
tion. In villages in which more than 10 participants were examined, between 10% and 49% of
those screened were found to be infected. LLM was15,000 mf/ml in 89 people. After screen-
ing for inclusion and exclusion criteria, 60 participants were randomized based on the LLM at
screening. Screen failure reasons are shown in Fig 1.
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Baseline characteristics
Table 2 summarizes the LLM data obtained during screening for Loa loa infection and at the
pre-treatment examination (M0, immediately before the first treatment) as well as other char-
acteristics of the participants. The LLM pre-treatment were in some participants significantly
different from the LLM at screening, with pre-treatment LLM ranging from 50% to around
500% of screening LLM. In two participants randomized to the 6x albendazole arm, the LLM
dropped from 15000 mf/ml at screening to 11040 mf/ml and 12700 mf/ml, respectively, at the
Fig 1. CONSORT flowchart. AE–adverse event, FU–follow up, M–Month, LLM—Loa loamicrofilaraemia measurement, LFU–Lost to FU, Tx–treatment.
doi:10.1371/journal.pntd.0004492.g001
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baseline examination. In eight participants randomized to placebo, five participants random-
ized to 2x albendazole and four participants randomized to 6x albendazole, the LLMmeasured
at baseline was so different from the LLM at screening (Fig 2) that it did not fall within the stra-
tum in which they had been randomized. This resulted in the imbalance in allocation to treat-
ment arms in the different strata when the pre-treatment values are evaluated. There was,
however, no statistically significant difference in pre-treatment LLMs between treatment arms
(Table 2). As expected, ALAT and ASAT levels were highly correlated (Spearman’s correlation
coefficient = 0.77), and only ALAT levels were used in the longitudinal trend analysis.
At baseline, seven participants had detectable levels ofMansonella perstansmicrofilariae
including one in the placebo group (440 mf/ml), four in the 2x albendazole group (120 mf/ml,
440 mf/ml, 700 mf/ml, 3820 mf/ml) and two in the 6x albendazole group (200 mf/ml, 1500 mf/
ml).
Proportion of participants with sustained (4 months long) LLM decrease by50% of
baseline value and a sustained LLM decrease to<8100 mf/ml. One participant in the pla-
cebo arm, two participants in the 2x albendazole arm and one participant in the 6x albendazole
Fig 2. Loa loamicrofilaraemia in individual participants by treatment group and geometric means of microfilaraemia by treatment group.mf per ml:
microfilaria per millilitre of blood.
doi:10.1371/journal.pntd.0004492.g002
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arm dropped out of the study before at least 3 consecutive LLMmeasurements to assess a 4
months long LLM decrease were obtained. They were thus not evaluable for the primary effi-
cacy analysis or the analysis of the proportion of participants with 4 months long reduction
of LLM to<8100 mf/ml (Fig 1).
Table 3 shows the number and proportion of evaluable participants with sustained LLM
decrease by50% from pre-treatment LLM at any time after randomisation and with a sus-
tained LLM of< 8100 mf/ml. The effect of 2x albendazole was not significantly different from
that of placebo for either endpoint. In contrast, the proportion of participants with a sustained
LLM decrease by50% from the pre-treatment was significantly higher in the 6x albendazole
arm than in the placebo arm. There was, however, no significant difference between these two
treatment arms in the proportion of participants with a sustained LLM decrease to<8100 mf/
ml.
Table 4 shows the treatment, the pre-treatment LLM, the first and last month at which a
sustained decrease of LLM by50 from pre-treatment, to<8100 mf/ml as well as to<30000
mf/ml were measured and the number of albendazole doses received prior to the start of the
sustained LLM decrease for each participant with a sustained LLM decrease by50% from
pre-treatment. The variability of the first month of any of the sustained LLM reductions and
the number of albendazole doses taken at that time suggests that factors other than an effect of
albendazole impact the LLM.
Reduction from pre-treatment value in Loa loamicrofilaraemia by time point. Fig 3
shows for each treatment arm and time point following the first treatment the maximum, 75th
percentile, median, 25th percentile and minimum of the percent reduction of LLM from the
value measured before the first treatment. Furthermore, Fig 3 includes the difference between
screening and pre-treatment LLM calculated as reduction in percent from pre-treatment value
(indicated as time point '-1' relative to treatment). It was included in the figure to facilitate
comparison of the post-treatment LLM reductions with the significant LLM changes which
occurred between screening and pre-treatment measurement. The large variations in the
change from pre-treatment value in both directions in each treatment group reflect the signifi-
cant intra- and inter-participant variation in LLM evident in Fig 2. Considering the low
Table 3. Proportion of participants with sustained ( 4 months) decrease in LLM by 50% from pre-treatment value and to < 8100 mf/ml.
Endpoint Placebo 2x Albendazole 6x Albendazole
Sustained reduction 50% from pre-treatment n/N1 (%) n/N1 (%) n/N1 (%)
Overall2 2/19 (10.5) 3/18 (16.7) 10/19 (52.6)
Stratum 15 000–30 000 mf/ml 0/5 2/10 (20.0) 6/10 (60.0)
Stratum 30 001–50 000 mf/ml 1/9 (11.1) 1/3 (33.3) 3/5 (60.0)
Stratum >50 000 mf/ml 1/5 (20.0) 0/5 (0) 1/4 (25.0)
Sustained reduction to <8100mf/ml n/N (%) n/N (%) n/N (%)
Overall3 0/19 2/18 (11.1) 4/19 (21.1)
Stratum 15 000–30 000 mf/ml 0/5 1/10 (10.0) 4/12 (33.3)
Stratum 30 001–50 000 mf/ml 0/9 1/3 (33.3%) 0/5
Stratum >50 000 mf/ml 0/5 0/5 0/4
1 N = number of participants evaluable, i.e. with  three successive LLM measurements following the 1st treatment allowing to assess whether the LLM
decrease lasted  4 months.
2 Fisher's exact test: Placebo vs. 2x Albendazole p = 0.66, Placebo vs. 6x Albendazole p = 0.01.
3 Fisher’s exact test: Placebo vs. 2x Albendazole p = 0.23, Placebo vs. 6x Albendazole p = 0.11.
doi:10.1371/journal.pntd.0004492.t003
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proportion of participants receiving 2x or 6x albendazole with sustained LLM reductions
reported in Table 3, descriptive analysis of the reductions by strata and sex was not performed.
Longitudinal trends in LLM from baseline to 11–12 months after completion of active
treatment. The results of the linear trend analysis (Table 5) confirm the conclusions from the
review of the LLM time courses (Fig 2) and the reduction from baseline (Fig 3). There was no
significant LLM change in the placebo or 2x albendazole group. The significant inter-partici-
pant variability in response to 6x albendazole (Fig 2, Fig 3, Table 5) is reflected in the very wide
95% confidence intervals of the regression coefficients.
Adverse events
Up to 2 months after the last albendazole or placebo dose administered, 15, 13 and 15 partici-
pants were found to have a total of 46, 48 and 45 adverse events, respectively, in the placebo, 2x
albendazole and 6x albendazole arm. None was regarded as study drug related. Across all par-
ticipants, the most frequently reported AEs were different types of pain (e.g. arthralgia, myal-
gia, back pain, pain in extremities) and malaria.
The AEs were of mild or moderate intensity except for three severe adverse events which
also met the criteria for SAEs (see Table 1). Upon unblinding, the participants with SAEs were
found to have been in the placebo group. One participant sustained a severe chest trauma in a
fight two days before the sixth treatment. One participant developed severe malaria and
typhoid fever one week after the first treatment and was excluded from further treatment.
Another participant, a 47 year old man, died 6 weeks after the 5th treatment; his death occurred
at home and was preceded by a short illness including fever, cough, seizure and coma. The
post-mortem was not able to establish the cause of death. The Loa loamicrofilaraemia was
40,000 mf/ml at screening, 197,000 mf/ml at baseline and 440,080 mf/ml, 332,060 mf/ml,
Table 4. Pre-treatment LLM, month of start and end of sustained ( 4 months) decrease in LLM by 50% from pre-treatment LLM, to < 8100mf/ml
or < 30000 mf/ml by treatment arm for participants with a sustained decrease by 50%.
Treatment,
participant number
Pre- treatment
LLM (sex)
Start to end1 of sustained
reduction by  50% (doses2)
Start to end1 of sustained
reduction to  8100 mf/ml
(doses2)
Start to end1 of sustained
reduction to <30000 mf/ml
(doses2)
Plac—15 46420 (F) M18-M24 NA M18-M24
Plac—17 90940 (M) M14-M24 NA NA
2x Alb—2 16600 (M) M14-M24 (2) M18-M24 (2) NA
2x Alb—10 28120 (F) M14-M24 (2) NA NA
2x Alb—13 34120 (M) M4-M24 (2) M14-M18 (2) M4-M24 (2)
6x Alb—1 11040 (F) M14-M24 (2) M10-M24 (5) NA
6x Alb—3 15500 (M) M6-M24 (3) M6-M24 (3) NA
6x Alb—5 22460 (F) M6-M24 (3) M10-M21 (4) NA
6x Alb—6 24520 (M) M14-M21 (6) M6-M18 (3) NA
6x Alb—7 25520 (M) M6-M21 (3) NA NA
6x Alb—8 27240 (M) M18-M24 (6) NA NA
6x Alb—12 32040 (M) M14-M24 (6) NA M2-M24 (1)
6x Alb -14 41180 (M) M18-M24 (6) NA M10-M24 (5)
6x Alb—15 42980 (M) M14-M24 (6) NA M10-M24 (5)
6x Alb—19 158400 (M) M10-M24 (5) NA NA
1 Start and end are provided as the month M of the ﬁrst and last measurement of the sustained LLM reduction.
2 Doses: number of albendazole doses received before the start of the sustained reduction. The ﬁrst dose was given at M0
NA: not achieved or not applicable (for reduction to <30000 mf/ml for participants with < 30000mf/ml pre-treatment LLM)
doi:10.1371/journal.pntd.0004492.t004
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410,200 mf/ml and 144,360 mf/ml two months after the first, second, third and fourth placebo
dose, respectively. The pathology found minor brain haemorrhages, suggesting that Loa loa
infection could have been a contributing factor.
Fig 3. Minimum, 25%, 50th, 75th percentile andmaximum of the % reduction from pre-treatment values. P placebo, 2x 2 doses albendazole, 6x 6
doses albendazole, -1 value obtained during screening (4–12 weeks prior to baseline measurement and first treatment), 2, 4, 6, 8, 10, 14, 18, 21, 24 Months
after the first treatment at which LLM was measured.
doi:10.1371/journal.pntd.0004492.g003
Table 5. Longitudinal trend in Loa loamicrofilaraemia from baseline up to 11–12 months after completion of each regimen.
Treatment arm Crude regression coefﬁcient (95% CI) 2 p-value Adjusted1 regression coefﬁcient (95% CI) 2 p-value
Placebo 0.99 (0.97–1.00) 0.21 0.99 (0.97–1.01) 0.21
2x albendazole 0.71 (0.46–1.10) 0.13 0.69 (0.44–1.09) 0.11
6x albendazole 0.69 (0.43–1.09) 0.11 0.59 (0.37–0.92) 0.02
The 2-doses regimen was completed at M2, and data from baseline up to month 14 included in the analysis; the 6-doses regimen was completed at M10,
and data from baseline to month 21 was included in the analysis. The analysis of the placebo group included the data up to month.
1 Adjustment for age, sex and baseline liver function (ALAT)
2 Regression coefﬁcients represent the ratio between geometric means of consecutive cross-sectional measurement within each group, hence describing
an exponential progression.
doi:10.1371/journal.pntd.0004492.t005
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Observations onM. perstansmicrofilariae levels
During the 24 month follow up period, 11 participants who did not have detectable levels ofM.
perstans at baseline, had detectable levels at least once. In some participants,M. perstans levels
varied significantly over time without any indication of an effect of 2x or 6x albendazole. The
M. perstansmicrofilariae levels in all participants in whom detectable levels were detected at
least once are shown in Fig 4.
Discussion
As anticipated based on prior knowledge of albendazole [27–30, 33–36], no mild, moderate or
severe adverse drug reactions were recorded.
This study evaluated whether a 2 dose and/or a 6 dose albendazole treatment regimen result
in a50% reduction in LLM from pre-treatment for at least 4 months. Depending on the
extent and duration of LLM reduction, the regimen could be considered for community wide
Fig 4. M. perstansmicrofilariae levels in participants in whomM. perstanswas detectable at least once during the study by treatment group.mf
per ml: microfilaria per millilitre of blood.
doi:10.1371/journal.pntd.0004492.g004
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treatment in Loa loa co-endemic areas before ivermectin or ivermectin-albendazole mass treat-
ment to reduce the risk of severe ADRs or SARs or for further improvement of the regimen.
The results show that only the 6 dose regimen had a LLM reducing effect. The time course
of LLM reduction, and the absence of adverse drug reactions known to occur upon treatment
of individuals with high LLM with microfilaricidal drugs support the conclusions from prior
studies [28–30] that the LLM reducing effect of albendazole is likely due to microfilariae dying
as they reach the end of their life span. They are not being replaced because albendazole bind-
ing to β-tubulin disrupts microtubule structure, function and formation which results in
macrofilariae starvation and inhibition of reproduction [37, 38].
Around 50% of participants in the 6x albendazole arm experienced a sustained LLM
decrease by 50%. None of the 9 participants with LLM>30000 mf/ml before treatment had
a sustained LLM decrease to<8100 mf/ml. The LLM lowering effect of the 6x albendazole regi-
men is therefore insufficient to significantly reduce the population at highest risk of severe
ADRs or SARs upon ivermectin mass treatment. This study thus adds to the body of data
showing insufficient efficacy of different regimens of albendazole for reducing LLM. In contrast
to our study, these studies included participants with pre-treatment LLM<8100 mf/ml, no or
an unspecified number of participants with LLM> 30000 mf/ml and the results were pre-
sented only via summary statistics across all participants [27–30].
The cost-benefit of further efforts to improve an albendazole based treatment regimen, e.g.
through sustained release formulation technology, for LLM reduction needs to be carefully
considered. These considerations need to take into account the dose- and time-dependent
pharmacokinetics of albendazole, including the inter-subject variability in albendazole bio-
availability and conversion to the active metabolite albendazole sulfoxide, the fact that albenda-
zole induces its own disposal during long term treatment resulting in decreasing levels of
albendazole sulfoxide [39–41], the potential toxicity associated with long term exposure
(http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020666s009lbl.pdf) and the time
and cost to develop an affordable, safe and efficacious dose. These considerations also need to
include the alternative drugs and approaches in development. An oral flubendazole formula-
tion is now being evaluated for clinical development for onchocerciasis [42]. Prior clinical data
suggest that flubendazole does not have a microfilaricidal effect, but leads to a slow reduction
in microfilariae levels through an effect on the O. volvulusmacrofilariae [43]. Large scale efforts
to discover novel antibiotics targeting theWolbachia endosymbionts in the filariae that cause
onchocerciasis and lymphatic filariasis are under way [44]. Doxycycline treatment of O. volvu-
lus infected individuals has provided proof-of-concept for the effect of antibiotics on the repro-
ductive activity and viability of the macrofilariae without microfilaricidal activity [45, 46]. One
study of doxycycline in O. volvulus infected people included 22 people with a pre-treatment
LLM of< 8000 mf/ml. No adverse events of the type and severity observed after ivermectin
treatment of people with high LLM were reported[47].
Alternate approaches to onchocerciasis and lymphatic filariasis control in Loa loa co-
endemic areas are under evaluation. This includes development of diagnostics for high levels of
infection with Loa loa to identify individuals at risk for severe ADRs and/or SARs to ivermectin
[48]. If the ongoing field testing is successful, Loa loa infected individuals at risk of ADRs/
SARs and co-infected with O. volvulus, could be treated with regimens of antibiotics already
shown to be effective against O. volvulus. The implementation of this approach, including the
'cut-off' for exclusion from ivermectin treatment and the time between LLMmeasurements
and treatment, needs to take into account the substantial intra-individual LLM variability
observed in the absence of treatment in this study (Table 2, Fig 2, Fig 3). Research on LLM vari-
ability within shorter intervals than the 1–4 months in our study may be needed to inform the
maximum time frame between LLMmeasurement and safe ivermectin treatment.
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The level of variability we observed in the absence as well as during and after treatment has
to our knowledge not previously been reported. It needs to be taken into account during review
of the other studies which evaluated the effect of albendazole regimens on LLM based on sum-
mary statistics [27–30]. Analysis of the data from this study via geometric mean LLM (Fig 2),
shows a progressive LLM decrease in the 6x albendazole arm fromM2-M14 to around 50% of
pretreatment levels. Only the review of the individual participant data (Fig 2, Table 3) showed
that this mean decrease was driven by only a few individuals and that start time relative to
treatment and the duration of LLM decrease differed between individuals (Table 4). Any treat-
ment to ensure safe ivermectin mass treatment has, however, to reduce LLM below the level of
risk in all to be treated with ivermectin and the start time relative to treatment and the duration
of the LLM decrease below the risk level needs to reliable. Consequently, LLM variability needs
to be taken into account in the design, analysis and reporting of all future studies on the effi-
cacy and safety of drugs or strategies for addressing loiasis as an obstacle for onchocerciasis
and lymphatic filariasis control and elimination and as a neglected disease that can negatively
impact people's health, well-being and health care costs.
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